{"id":1226,"date":"2026-03-12T17:26:59","date_gmt":"2026-03-12T16:26:59","guid":{"rendered":"https:\/\/biotechlerncenter.iph-multisite.berta-bewegt.ch\/?page_id=1226"},"modified":"2026-03-12T17:26:59","modified_gmt":"2026-03-12T16:26:59","slug":"6-deux-approches-des-immunotherapies","status":"publish","type":"page","link":"https:\/\/biotechlerncenter.interpharma.ch\/fr\/sujets\/immuno-oncologie\/6-deux-approches-des-immunotherapies\/","title":{"rendered":"6. Deux approches des immunoth\u00e9rapies"},"content":{"rendered":"\n<p>En d\u00e9pit de ces difficult\u00e9s, des chercheuses et chercheurs du monde entier parviennent r\u00e9guli\u00e8rement \u00e0 d\u00e9velopper et \u00e0 lancer de nouvelles immunoth\u00e9rapies. Ils poursuivent fondamentalement deux approches diff\u00e9rentes:<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Substances actives<\/h2>\n\n\n\n<p><strong>Inhibiteurs de points de contr\u00f4le: desserrer le frein \u00e0 main<\/strong><\/p>\n\n\n\n<p>La premi\u00e8re possibilit\u00e9 pour renforcer le syst\u00e8me immunitaire dans la lutte contre les cellules canc\u00e9reuses est appel\u00e9e inhibiteurs de points de contr\u00f4le immunitaires. Normalement, les prot\u00e9ines des points de contr\u00f4le emp\u00eachent le syst\u00e8me immunitaire de r\u00e9agir excessivement. Les cellules canc\u00e9reuses utilisent cette fonction: elles produisent de telles prot\u00e9ines et les pr\u00e9sentent \u00e0 leur surface, faisant ainsi croire au syst\u00e8me immunitaire qu\u2019elles sont inoffensives.<br>Les inhibiteurs de point de contr\u00f4le sont des substances actives qui bloquent ces prot\u00e9ines et permettent donc au syst\u00e8me immunitaire de reconna\u00eetre la v\u00e9rit\u00e9: il s\u2019agit de cellules canc\u00e9reuses.<br>On peut utiliser les inhibiteurs de point de contr\u00f4le contre de nombreux types de cancer, on a d\u00e9j\u00e0 enregistr\u00e9 de bons r\u00e9sultats dans le traitement du cancer du poumon et du cancer de la peau.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Cellules<\/h2>\n\n\n\n<p><strong>Lymphocytes T: booster le syst\u00e8me immunitaire<\/strong><\/p>\n\n\n\n<p>Ce processus ne consiste pas \u00e0 administrer des substances actives, mais des cellules. Des cellules immunitaires (appel\u00e9es lymphocytes T ou cellules T) sont pr\u00e9lev\u00e9es au patient et g\u00e9n\u00e9tiquement modifi\u00e9es pour qu\u2019elles pr\u00e9sentent \u00e0 leur surface une mol\u00e9cule (une sorte d\u2019antenne) capable de reconna\u00eetre les cellules canc\u00e9reuses en se liant \u00e0 l\u2019antig\u00e8ne tumoral CD19. D\u00e8s que le lymphocyte T modifi\u00e9 d\u00e9tecte une cellule canc\u00e9reuse, il commence \u00e0 se multiplier. Un tel lymphocyte T est capable de d\u00e9truire 1000 cellules canc\u00e9reuses.<br>Un point int\u00e9ressant est que cette technique est utilisable contre de nombreux autres types de cancer, en particulier la leuc\u00e9mie (cancer du sang) et les lymphomes (cancers du syst\u00e8me lymphatique).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>En d\u00e9pit de ces difficult\u00e9s, des chercheuses et chercheurs du monde entier parviennent r\u00e9guli\u00e8rement \u00e0 d\u00e9velopper et \u00e0 lancer de nouvelles immunoth\u00e9rapies. Ils poursuivent fondamentalement deux approches diff\u00e9rentes: Substances actives Inhibiteurs de points de contr\u00f4le: desserrer le frein \u00e0 main La premi\u00e8re possibilit\u00e9 pour renforcer le syst\u00e8me immunitaire dans la lutte contre les cellules canc\u00e9reuses [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":544,"menu_order":5,"comment_status":"closed","ping_status":"closed","template":"page-templates\/unterthema.php","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"class_list":["post-1226","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.2 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>6. Deux approches des immunoth\u00e9rapies - biotechlerncenter<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/biotechlerncenter.interpharma.ch\/themen\/immun-onkologie\/6-zwei-ansaetze-von-immuntherapien\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"6. Deux approches des immunoth\u00e9rapies\" \/>\n<meta property=\"og:description\" content=\"En d\u00e9pit de ces difficult\u00e9s, des chercheuses et chercheurs du monde entier parviennent r\u00e9guli\u00e8rement \u00e0 d\u00e9velopper et \u00e0 lancer de nouvelles immunoth\u00e9rapies. Ils poursuivent fondamentalement deux approches diff\u00e9rentes: Substances actives Inhibiteurs de points de contr\u00f4le: desserrer le frein \u00e0 main La premi\u00e8re possibilit\u00e9 pour renforcer le syst\u00e8me immunitaire dans la lutte contre les cellules canc\u00e9reuses [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/biotechlerncenter.interpharma.ch\/themen\/immun-onkologie\/6-zwei-ansaetze-von-immuntherapien\/\" \/>\n<meta property=\"og:site_name\" content=\"biotechlerncenter\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/biotechlerncenter.interpharma.ch\/themen\/immun-onkologie\/6-zwei-ansaetze-von-immuntherapien\/\",\"url\":\"https:\/\/biotechlerncenter.interpharma.ch\/themen\/immun-onkologie\/6-zwei-ansaetze-von-immuntherapien\/\",\"name\":\"6. Deux approches des immunoth\u00e9rapies - biotechlerncenter\",\"isPartOf\":{\"@id\":\"https:\/\/biotechlerncenter.interpharma.ch\/#website\"},\"datePublished\":\"2026-03-12T16:26:59+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/biotechlerncenter.interpharma.ch\/themen\/immun-onkologie\/6-zwei-ansaetze-von-immuntherapien\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/biotechlerncenter.interpharma.ch\/themen\/immun-onkologie\/6-zwei-ansaetze-von-immuntherapien\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/biotechlerncenter.interpharma.ch\/themen\/immun-onkologie\/6-zwei-ansaetze-von-immuntherapien\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\/\/biotechlerncenter.interpharma.ch\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sujets\",\"item\":\"https:\/\/biotechlerncenter.interpharma.ch\/fr\/sujets\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Immuno-oncologie\",\"item\":\"https:\/\/biotechlerncenter.interpharma.ch\/fr\/sujets\/immuno-oncologie\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"6. Deux approches des immunoth\u00e9rapies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/biotechlerncenter.interpharma.ch\/#website\",\"url\":\"https:\/\/biotechlerncenter.interpharma.ch\/\",\"name\":\"biotechlerncenter\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/biotechlerncenter.interpharma.ch\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"6. Deux approches des immunoth\u00e9rapies - biotechlerncenter","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/biotechlerncenter.interpharma.ch\/themen\/immun-onkologie\/6-zwei-ansaetze-von-immuntherapien\/","og_locale":"fr_FR","og_type":"article","og_title":"6. Deux approches des immunoth\u00e9rapies","og_description":"En d\u00e9pit de ces difficult\u00e9s, des chercheuses et chercheurs du monde entier parviennent r\u00e9guli\u00e8rement \u00e0 d\u00e9velopper et \u00e0 lancer de nouvelles immunoth\u00e9rapies. Ils poursuivent fondamentalement deux approches diff\u00e9rentes: Substances actives Inhibiteurs de points de contr\u00f4le: desserrer le frein \u00e0 main La premi\u00e8re possibilit\u00e9 pour renforcer le syst\u00e8me immunitaire dans la lutte contre les cellules canc\u00e9reuses [&hellip;]","og_url":"https:\/\/biotechlerncenter.interpharma.ch\/themen\/immun-onkologie\/6-zwei-ansaetze-von-immuntherapien\/","og_site_name":"biotechlerncenter","twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/biotechlerncenter.interpharma.ch\/themen\/immun-onkologie\/6-zwei-ansaetze-von-immuntherapien\/","url":"https:\/\/biotechlerncenter.interpharma.ch\/themen\/immun-onkologie\/6-zwei-ansaetze-von-immuntherapien\/","name":"6. Deux approches des immunoth\u00e9rapies - biotechlerncenter","isPartOf":{"@id":"https:\/\/biotechlerncenter.interpharma.ch\/#website"},"datePublished":"2026-03-12T16:26:59+00:00","breadcrumb":{"@id":"https:\/\/biotechlerncenter.interpharma.ch\/themen\/immun-onkologie\/6-zwei-ansaetze-von-immuntherapien\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/biotechlerncenter.interpharma.ch\/themen\/immun-onkologie\/6-zwei-ansaetze-von-immuntherapien\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/biotechlerncenter.interpharma.ch\/themen\/immun-onkologie\/6-zwei-ansaetze-von-immuntherapien\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/biotechlerncenter.interpharma.ch\/fr\/"},{"@type":"ListItem","position":2,"name":"Sujets","item":"https:\/\/biotechlerncenter.interpharma.ch\/fr\/sujets\/"},{"@type":"ListItem","position":3,"name":"Immuno-oncologie","item":"https:\/\/biotechlerncenter.interpharma.ch\/fr\/sujets\/immuno-oncologie\/"},{"@type":"ListItem","position":4,"name":"6. Deux approches des immunoth\u00e9rapies"}]},{"@type":"WebSite","@id":"https:\/\/biotechlerncenter.interpharma.ch\/#website","url":"https:\/\/biotechlerncenter.interpharma.ch\/","name":"biotechlerncenter","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/biotechlerncenter.interpharma.ch\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"}]}},"_links":{"self":[{"href":"https:\/\/biotechlerncenter.interpharma.ch\/fr\/wp-json\/wp\/v2\/pages\/1226","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/biotechlerncenter.interpharma.ch\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/biotechlerncenter.interpharma.ch\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/biotechlerncenter.interpharma.ch\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/biotechlerncenter.interpharma.ch\/fr\/wp-json\/wp\/v2\/comments?post=1226"}],"version-history":[{"count":1,"href":"https:\/\/biotechlerncenter.interpharma.ch\/fr\/wp-json\/wp\/v2\/pages\/1226\/revisions"}],"predecessor-version":[{"id":1227,"href":"https:\/\/biotechlerncenter.interpharma.ch\/fr\/wp-json\/wp\/v2\/pages\/1226\/revisions\/1227"}],"up":[{"embeddable":true,"href":"https:\/\/biotechlerncenter.interpharma.ch\/fr\/wp-json\/wp\/v2\/pages\/544"}],"wp:attachment":[{"href":"https:\/\/biotechlerncenter.interpharma.ch\/fr\/wp-json\/wp\/v2\/media?parent=1226"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}